Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06342466 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Bortezomib, Pomalidomide, Dexamethasone for Systemic AL Amyloidosis

StatusRecruiting
PhasePhase 2
SponsorJin Lu, MD
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Site contact updated
    • Eligibility criteria expanded, about 3 words
    v3
  2. Start date changed from estimate of Apr 2024 to May 6, 2024v2
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Jin Lu, MD
2 trials monitored
See all monitored trials
Amyloidosis
330 trials monitored
See 20 trials at risk
This is an open-label, multicenter, Phase 2 study in subjects with newly diagnosed or previous treated systemic light chain (AL) amyloidosis. Approximately 40 subjects will receive therapy with bortezomib, pomalidomide, and dexamethasone. The primary outcome is hematologic very good partial response and complete response rate at 6 months.
Trial Details
NCT Number NCT06342466
Lead Sponsor Jin Lu, MD
Conditions
(from sponsor)		 Systemic Amyloidosis
Related terms Immunoglobulin Light-chain Amyloidosis
Enrollment 40 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov